Table 3.

Best-fit parameter values obtained from comparisons of model predictions Eq. (S1) in (14)] with data from patients treated with telaprevir plus PEG-IFN-α-2a for two weeks.

Patient	ρT (day-1)	δ (day-1)	${\epsilon }_{\mathit{total}}^s$	${\epsilon }_{\mathit{total}}^r$	β (10-8 mL day-1 virion-1)	ps (virions cell-1 day-1)	Infected cells at baseline* (%)	Increase in total hepatocytes (%)
1001	0.83	0.93	0.99951	0.68	4.77	80.07	5.4	49
1005	0.31	0.29	0.99832	0.82	7.27	5.90	4.2	8
3007	1.12	0.33	0.99984	0.77	8.34	18.47	14	40
3009	1.76	0.55	0.99980	0.95	0.57	132.52	8.3	8
3011	0.92	0.18	0.99810	0.91	0.76	38.36	12	7
3013	2.20	0.51	0.99950	0.95	1.27	52.17	8.0	5
3016	1.24	0.46	0.99961	0.70	9.63	13.31	13	28
3019	1.65	0.44	0.99937	0.78	11.29	20.57	15	43
Average±SD	1.25±0.60	0. 46±0.23	0.99930±0.00067	0.82±0.11	5.49±4.26	45.17±42.79	10±4.1	24±19

^*We assumed that half the maximum number of hepatocytes are not targets of HCV infection during data fitting. Similar sensitivity analysis of data fitting to the choice of N was addressed in the remarks of Table 2.